Sources: EQT Partners to team with Actavis in Ratiopharm bid

EQT Partners AB, the last private-equity bidder for German generic-drug maker Ratiopharm GmbH, is seeking to team up with Actavis Group to bolster its chances of beating large pharmaceutical companies like Pfizer in the auction, said three people familiar with the matter. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.